AstraZeneca Pharma India Ltd

AstraZeneca India to Launch Soliris (Eculizumab) in August 2025 💊

- AstraZeneca Pharma India will launch Eculizumab (Soliris) in August 2025 in India.

- The drug is indicated for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS).

- It works by inhibiting complement-mediated thrombotic microangiopathy.

- The company has secured Import and Market Permission (Form CT-20) for Eculizumab concentrate (300 mg/10mg/ml).